Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 12Breast 6Tumor-Agnostic 5Lymphoid 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 5Neoplasm Metastasis 2Carcinoma 1

Interventions

Surveys and Questionnaires 65pembrolizumab 56Gemcitabine 54Paclitaxel 51Blood Specimen Collection 45Carboplatin 44Bevacizumab 41Docetaxel 38Cisplatin 33Nivolumab 32Fluorouracil 31Capecitabine 28Radiotherapy 25Pemetrexed 25Irinotecan 25Standard of Care 24Interviews as Topic 24Magnetic Resonance Spectroscopy 23Leucovorin 22Erlotinib Hydrochloride 22atezolizumab 21Cetuximab 21Afatinib 21Oxaliplatin 19trametinib 18Exercise 18Ipilimumab 17Sorafenib 16Cyclophosphamide 16olaparib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasms × liposomal doxorubicin × Tumor-Agnostic × Clear all
NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
38 enrolled
Tumor-Agnostic

Neoplasms

NCT02483247 2023-11-14

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
165 enrolled
Tumor-Agnostic

Neoplasms

NCT01110603 2016-05-05

A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

Tesaro, Inc.

Phase 1 Terminated
12 enrolled
Tumor-Agnostic

Neoplasms

NCT01455532 2014-10-22

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Sanofi

Phase 1 Completed
59 enrolled
Tumor-Agnostic

Neoplasms

NCT00183742 2014-05-22

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

University of Southern California

Phase 1 Completed
35 enrolled
Tumor-Agnostic

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡